These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26345293)

  • 1. Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer.
    Xiao X; Wang S; Xia S; Zou M; Li Y; Wei Y; Mei Q; Chen Y
    Onco Targets Ther; 2015; 8():2209-14. PubMed ID: 26345293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
    Liu ZL; Wang B; Liu JZ; Liu WW
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1076-S1083. PubMed ID: 30539849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
    Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
    J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.
    Shi Y; Hu Y; Hu X; Li X; Lin L; Han X
    Thorac Cancer; 2015 Nov; 6(6):785-91. PubMed ID: 26557919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial.
    Pan D; Hou M; Li H; Yu P; Liu J
    Zhongguo Fei Ai Za Zhi; 2006 Oct; 9(5):443-6. PubMed ID: 21176468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
    Kim DW; Kim HG; Kim JH; Park K; Kim HK; Jang JS; Kim BS; Kang JH; Lee KH; Kim SW; Ryoo HM; Kim JS; Lee KH; Kwon JH; Choi JH; Shin SW; Hahn S; Heo DS
    Cancer Res Treat; 2019 Jan; 51(1):119-127. PubMed ID: 29529858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
    Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
    Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
    Ni J; Si X; Wang H; Zhang X; Zhang L
    Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
    J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
    Schmittel A; Fischer von Weikersthal L; Sebastian M; Martus P; Schulze K; Hortig P; Reeb M; Thiel E; Keilholz U
    Ann Oncol; 2006 Apr; 17(4):663-7. PubMed ID: 16423848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
    Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of EP Chemotherapy Followed by IP Chemotherapy Combined with Radiotherapy in the Treatment of Extensive-Stage Small-Cell Lung Cancer.
    Kang S; Lai CORXWZJHYZDCJ
    J BUON; 2021; 26(2):306-312. PubMed ID: 34076973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
    Yang CL; Ma LX; Sun SY; Cui HX; Li ZL; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):454-9. PubMed ID: 27346404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review.].
    Yao N; Jiang L; Yang K; Ye Y; Mi D; Min G
    Zhongguo Fei Ai Za Zhi; 2009 Aug; 12(8):884-8. PubMed ID: 20719176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
    Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
    BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
    Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
    Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
    William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
    Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.